• Portal Therapeutics webinar

    On Tuesday, June 23, Portal Therapeutics (a @GondolaBio affiliate company) is hosting an in-depth webinar reviewing the Phase 2a GATEWAY study data for PORT-77 in erythropoietic protoporphyria (EPP). For clinicians managing rare porphyrias, this session will offer valuable insights into: The latest clinical safety and efficacy data. PORT-77’s mechanism of action. Upcoming clinical development pathways […]